UY37694A - Dominios de unión a antígeno humanizados y métodos de uso - Google Patents

Dominios de unión a antígeno humanizados y métodos de uso

Info

Publication number
UY37694A
UY37694A UY0001037694A UY37694A UY37694A UY 37694 A UY37694 A UY 37694A UY 0001037694 A UY0001037694 A UY 0001037694A UY 37694 A UY37694 A UY 37694A UY 37694 A UY37694 A UY 37694A
Authority
UY
Uruguay
Prior art keywords
humanized
region
methods
antibody
humanized antigen
Prior art date
Application number
UY0001037694A
Other languages
English (en)
Inventor
A Sievers Stuart
J W Wiltzius Jed
Original Assignee
Kite Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kite Pharma Inc filed Critical Kite Pharma Inc
Publication of UY37694A publication Critical patent/UY37694A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Abstract

La invención provee un anticuerpo anti-CD19 humanizado o un fragmento de unión al antígeno de este que comprende una región variable de cadena ligera (VL) y una de cadena pesada (VH) en el que las regiones VL y VL humanizadas derivan del anticuerpo FMC63 clon anti-CD19 de ratón; la región VL humanizada y/o la región VH humanizada comprenden una o más sustituciones de aminoácidos en la región marco. El anticuerpo anti-CD19 humanizado o fragmento de unión al antígeno puede ser parte de un fragmento variable de cadena simple (scFv), un receptor de antígenos quiméricos o un receptor de linfocitos T.
UY0001037694A 2017-04-24 2018-04-24 Dominios de unión a antígeno humanizados y métodos de uso UY37694A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762489258P 2017-04-24 2017-04-24

Publications (1)

Publication Number Publication Date
UY37694A true UY37694A (es) 2018-11-30

Family

ID=62117162

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037694A UY37694A (es) 2017-04-24 2018-04-24 Dominios de unión a antígeno humanizados y métodos de uso

Country Status (16)

Country Link
US (2) US10844120B2 (es)
EP (2) EP3615146B1 (es)
JP (3) JP6975841B2 (es)
KR (3) KR20230006027A (es)
CN (1) CN110545883B (es)
AR (1) AR111418A1 (es)
AU (2) AU2018257894A1 (es)
BR (1) BR102018008260A2 (es)
CA (1) CA3060426A1 (es)
ES (1) ES2963598T3 (es)
JO (1) JOP20180042A1 (es)
PT (1) PT3615146T (es)
SG (2) SG11201909499QA (es)
TW (1) TWI768034B (es)
UY (1) UY37694A (es)
WO (1) WO2018200496A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11458167B2 (en) 2015-08-07 2022-10-04 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
US11390655B2 (en) * 2017-11-16 2022-07-19 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
CN113166253B (zh) * 2018-11-29 2023-04-28 浙江瑞加美生物科技有限公司 具有在CDR1区突变的人源化CD19 scFv的CAR-T细胞
CN109575143B (zh) * 2018-12-29 2022-06-17 博生吉医药科技(苏州)有限公司 双特异性cd20-cd19-car及其应用
CN109734813B (zh) * 2019-01-28 2022-06-17 广东昭泰体内生物医药科技有限公司 一种嵌合抗原受体及其应用
WO2020162452A1 (ja) * 2019-02-04 2020-08-13 国立大学法人愛媛大学 ＣＡＲライブラリおよびｓｃＦｖの製造方法
WO2020180551A1 (en) * 2019-03-05 2020-09-10 Promab Biotechnologies, Inc. Car-t cells with humanized cd19 scfv
WO2020180882A1 (en) * 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
CN114341176A (zh) * 2019-04-08 2022-04-12 纪念斯隆凯特琳癌症中心 Cd19抗体及其使用方法
CA3138707A1 (en) * 2019-05-03 2020-11-12 Kite Pharma, Inc. Methods of administering chimeric antigen receptor immunotherapy
CN112204135A (zh) * 2019-07-06 2021-01-08 苏州克睿基因生物科技有限公司 一种表达cd3抗体受体复合物的免疫细胞及其用途
WO2021004400A1 (zh) * 2019-07-06 2021-01-14 苏州克睿基因生物科技有限公司 一种表达cd3抗体受体复合物的免疫细胞及其用途
CN111187352B (zh) * 2020-01-17 2020-11-03 南京蓝盾生物科技有限公司 靶向人cd19的嵌合抗原受体及其应用
CN113307871B (zh) * 2020-02-27 2023-05-02 福州拓新天成生物科技有限公司 新型抗cd19抗体和cd19-car-t细胞的制备及其应用
BR112022017595A2 (pt) * 2020-03-03 2022-10-18 Systimmune Inc Anticorpos anti-cd19 e métodos de uso e fabricação dos mesmos
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
CN111518219B (zh) * 2020-05-08 2021-06-22 浙江大学 嵌合性抗原受体及表达其的巨噬细胞、调节巨噬细胞极化的方法和应用
US20230250188A1 (en) * 2020-06-11 2023-08-10 National University Corporation Kochi University Humanized Anti-GPC-1 Antibody
CN114163532A (zh) * 2020-09-10 2022-03-11 南京北恒生物科技有限公司 包含新型共刺激结构域的嵌合抗原受体及其用途
CN112375146B (zh) * 2021-01-07 2021-04-13 北京百普赛斯生物科技股份有限公司 检测Anti-CD19 CAR表达水平的抗独特性抗体及其应用
CN114957481A (zh) * 2021-02-25 2022-08-30 华夏英泰（北京）生物技术有限公司 针对cd19和cd22的双靶点star
WO2023208157A1 (zh) * 2022-04-29 2023-11-02 上海先博生物科技有限公司 靶向cd19的嵌合抗原受体及其应用
WO2024020063A2 (en) * 2022-07-19 2024-01-25 La Jolla Institute For Immunology Anti-hrf antibodies

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US20030036654A1 (en) 1994-08-18 2003-02-20 Holt Dennis A. Synthetic multimerizing agents
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
JP2004500095A (ja) 2000-02-24 2004-01-08 エクサイト　セラピーズ，　インコーポレイテッド 細胞の同時の刺激および濃縮
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
CL2007003622A1 (es) * 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
CN102421800A (zh) * 2009-02-23 2012-04-18 格兰马克药品股份有限公司 结合cd19的人源化抗体及其用途
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
EP3467101A3 (en) 2010-09-08 2019-06-19 Baylor College of Medicine Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells
CN106220739A (zh) 2010-12-09 2016-12-14 宾夕法尼亚大学董事会 嵌合抗原受体‑修饰的t细胞治疗癌症的用途
BR112013018311A2 (pt) 2011-01-18 2017-03-21 Univ Pennsylvania sequência de ácido nucleico isolada, receptor de antígeno quimérico isolado, célula t geneticamente modificada, vetor, e, uso de uma célula t geneticamente modificada.
US9024028B2 (en) 2011-01-26 2015-05-05 Ariad Pharmaceuticals, Inc. Methods and compositions for the synthesis of multimerizing agents
KR101976882B1 (ko) 2011-03-23 2019-05-09 프레드 헛친슨 켄서 리서치 센터 세포 면역요법용 방법 및 조성물
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
MX2014003176A (es) 2011-09-16 2015-08-05 Univ Pennsylvania Celulas t diseñadas mediante arn para el tratamiento de cancer.
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
SI3613439T1 (sl) 2013-02-15 2021-11-30 The Regents Of The University Of California Himerni antigenski receptor in postopki njegove uporabe
KR20150131218A (ko) 2013-03-14 2015-11-24 벨리쿰 파마슈티컬스, 인크. T 세포 증식의 제어 방법
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
CN105408473B9 (zh) 2013-05-14 2021-09-17 得克萨斯州大学系统董事会 工程化嵌合抗原受体(car)t细胞的人应用
DK3027204T3 (da) 2013-07-29 2022-04-19 2Seventy Bio Inc Flerdelte signaleringsproteiner og anvendelser deraf
US20160376375A1 (en) 2013-11-27 2016-12-29 Baylor College Of Medicine CSGP4 - Specific Chimeric Antigen Receptor for Cancer
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
EP3104866A4 (en) 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
TWI751102B (zh) * 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
WO2016044745A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
RU2727451C2 (ru) 2014-12-05 2020-07-21 Сити Оф Хоуп Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1
US10493139B2 (en) * 2015-07-24 2019-12-03 Innovative Cellular Therapeutics CO., LTD. Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
EP3149046B1 (en) * 2015-07-24 2020-02-26 Innovative Cellular Therapeutics Co., Ltd. Humanized anti-cd19 antibody and use thereof

Also Published As

Publication number Publication date
KR102481262B1 (ko) 2022-12-26
CA3060426A1 (en) 2018-11-01
BR102018008260A2 (pt) 2020-04-28
AR111418A1 (es) 2019-07-10
CN110545883B (zh) 2024-04-02
SG10201912400VA (en) 2020-02-27
TWI768034B (zh) 2022-06-21
EP3615146A1 (en) 2020-03-04
KR20220025904A (ko) 2022-03-03
JP6975841B2 (ja) 2021-12-01
TW202233691A (zh) 2022-09-01
JP2020517302A (ja) 2020-06-18
AU2018257894A1 (en) 2019-10-31
JP7434250B2 (ja) 2024-02-20
US20180312588A1 (en) 2018-11-01
US10844120B2 (en) 2020-11-24
WO2018200496A1 (en) 2018-11-01
PT3615146T (pt) 2023-11-27
SG11201909499QA (en) 2019-11-28
KR20190141211A (ko) 2019-12-23
JOP20180042A1 (ar) 2019-01-30
JP2024056792A (ja) 2024-04-23
CN110545883A (zh) 2019-12-06
JP2022028750A (ja) 2022-02-16
US20210061910A1 (en) 2021-03-04
KR102363742B1 (ko) 2022-02-17
EP3615146B1 (en) 2023-11-01
ES2963598T3 (es) 2024-04-01
KR20230006027A (ko) 2023-01-10
AU2021212061A1 (en) 2021-08-26
TW201902928A (zh) 2019-01-16
EP4286415A2 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
UY37694A (es) Dominios de unión a antígeno humanizados y métodos de uso
ECSP20024555A (es) Anticuerpos especificos para cd47 y pd-l1
EA201891694A1 (ru) Фармацевтическая композиция, содержащая конструкты биспецифических антител
EA201990331A1 (ru) Мультиспецифические антигенсвязывающие белки и способы их применения
CR20170026A (es) Anticuerpos anti-tau humanizados
CU24663B1 (es) Dominio de unión a antígeno anti-trbc1, receptor de antígeno quimérico, anticuerpo y acoplador biespecífico de células t que comprenden el mismo
CR20170383A (es) Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
EA201890302A1 (ru) Химерные рецепторы антигенов на основе однодоменных антител и способы их применения
MX2022012749A (es) Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
NZ728749A (en) Anti-pd-l1 antibodies
AU2016320748A8 (en) Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
NZ732628A (en) Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof
AR105267A1 (es) Anticuerpos de unión a tau
PE20160690A1 (es) Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos
PE20230381A1 (es) Proteina de union a rgma
NI201800113A (es) Anticuerpos anti-basigin humanizados y uso de los mismos.
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
PE20171060A1 (es) Receptores quimericos de antigeno anti-cldn y metodos de uso
CO2017004753A2 (es) Anticuerpos que se unen a ccr6
JOP20190246A1 (ar) جسم مضاد أحادي النسيلة لـ pd-l1
NZ728981A (en) Anti-ceramide antibodies
MX2019011585A (es) Anticuerpos miltiespecificos estables.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231103